Psychiatric manifestations of Kleefstra syndrome: a case report.

Kleefstra syndrome autism spectrum disorder case report intellectual disability psychiatric manifestations

Journal

Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006

Informations de publication

Date de publication:
2023
Historique:
received: 26 02 2023
accepted: 10 07 2023
medline: 14 8 2023
pubmed: 14 8 2023
entrez: 14 8 2023
Statut: epublish

Résumé

Kleefstra syndrome is a rare genetic condition, which affects at least 1 in 120,000 individuals who have a neurodevelopmental disorder, characterized by the core clinical phenotype of intellectual disability, hypotonia, severe speech delay, and distinct facial characteristics with additional clinical features including sleep disturbance, overweight, psychiatric disorders, and autism spectrum disorder. To date, a limited number of case reports of Kleefstra syndrome with psychiatric manifestations have been reported. We reported a case of a 35-year-old male diagnosed with Kleefstra syndrome, who also had diagnoses of autism spectrum disorder and moderate to severe intellectual disability. He exhibited various psychiatric manifestations, including temporarily manic-like symptoms, excessive eating/overweight, addictive/gambling behaviors, inappropriate and unsafe internet use, sleep disturbance, rigid routines, and behaviors that challenged in the form of meltdowns. These symptoms were eventually relatively successfully managed with a combination of non-pharmacological and pharmacological treatments. To our knowledge, there is only a limited number of case reports that detail patients with Kleefstra syndrome exhibiting various psychiatric manifestations. Our report adds further knowledge to the paucity of literature and highlights the effectiveness of a combination of non-pharmacological and pharmacological treatments for behavioral/psychiatric difficulties in Kleefstra syndrome.

Sections du résumé

Background UNASSIGNED
Kleefstra syndrome is a rare genetic condition, which affects at least 1 in 120,000 individuals who have a neurodevelopmental disorder, characterized by the core clinical phenotype of intellectual disability, hypotonia, severe speech delay, and distinct facial characteristics with additional clinical features including sleep disturbance, overweight, psychiatric disorders, and autism spectrum disorder. To date, a limited number of case reports of Kleefstra syndrome with psychiatric manifestations have been reported.
Case presentation UNASSIGNED
We reported a case of a 35-year-old male diagnosed with Kleefstra syndrome, who also had diagnoses of autism spectrum disorder and moderate to severe intellectual disability. He exhibited various psychiatric manifestations, including temporarily manic-like symptoms, excessive eating/overweight, addictive/gambling behaviors, inappropriate and unsafe internet use, sleep disturbance, rigid routines, and behaviors that challenged in the form of meltdowns. These symptoms were eventually relatively successfully managed with a combination of non-pharmacological and pharmacological treatments.
Conclusion UNASSIGNED
To our knowledge, there is only a limited number of case reports that detail patients with Kleefstra syndrome exhibiting various psychiatric manifestations. Our report adds further knowledge to the paucity of literature and highlights the effectiveness of a combination of non-pharmacological and pharmacological treatments for behavioral/psychiatric difficulties in Kleefstra syndrome.

Identifiants

pubmed: 37575568
doi: 10.3389/fpsyt.2023.1174195
pmc: PMC10416101
doi:

Types de publication

Case Reports

Langues

eng

Pagination

1174195

Informations de copyright

Copyright © 2023 Yoshida, Müller and Desarkar.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

BMC Psychiatry. 2021 Feb 17;21(1):105
pubmed: 33596853
Am J Hum Genet. 2006 Aug;79(2):370-7
pubmed: 16826528
Am J Med Genet A. 2004 Aug 1;128A(4):340-51
pubmed: 15264279
Eur J Clin Pharmacol. 2019 Apr;75(4):437-450
pubmed: 30511328
Mol Genet Genomic Med. 2016 Dec 26;5(2):130-140
pubmed: 28361099
Clin Neuropharmacol. 2017 Jul/Aug;40(4):185-188
pubmed: 28622207
Mol Syndromol. 2012 Apr;2(3-5):202-212
pubmed: 22670141
Psychiatr Genet. 2023 Feb 1;33(1):34-36
pubmed: 36617745
Neurocase. 2021 Jun;27(3):227-230
pubmed: 34010111
Brain Res. 2011 Mar 22;1380:42-77
pubmed: 21129364
J Med Genet. 2009 Sep;46(9):598-606
pubmed: 19264732

Auteurs

Kazunari Yoshida (K)

Azrieli Adult Neurodevelopmental Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Tanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.

Daniel J Müller (DJ)

Tanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Würzburg, Germany.

Pushpal Desarkar (P)

Azrieli Adult Neurodevelopmental Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
Adult Neurodevelopmental Services, Centre for Addiction and Mental Health, Toronto, ON, Canada.

Classifications MeSH